Compare JOE & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | BEAM |
|---|---|---|
| Founded | 1936 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2002 | 2019 |
| Metric | JOE | BEAM |
|---|---|---|
| Price | $64.02 | $33.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $50.75 |
| AVG Volume (30 Days) | 220.1K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | 56.69 | ★ 82.31 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $513,246,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.77 |
| P/E Ratio | $266.83 | ★ N/A |
| Revenue Growth | 27.44 | ★ 33.33 |
| 52 Week Low | $45.75 | $15.60 |
| 52 Week High | $73.54 | $36.44 |
| Indicator | JOE | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 63.31 |
| Support Level | $63.02 | $25.85 |
| Resistance Level | $66.80 | $34.29 |
| Average True Range (ATR) | 1.47 | 1.84 |
| MACD | 0.06 | 0.34 |
| Stochastic Oscillator | 27.87 | 87.60 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.